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Fates of Murine Pluripotent Stem Cell-Derived Neural Progenitors
Following Transplantation Into Mouse Cochleae
Koji Nishimura, Takayuki Nakagawa, Tatsunori Sakamoto, and Juichi Ito
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
This study evaluated the tumorigenesis risk of induced pluripotent stem (iPS) cells after transplantation into
the cochlea. One mouse embryonic stem (ES) cell line and three mouse iPS cell lines, one derived from
adult mouse tail-tip fibroblasts (TTFs) and two from mouse embryonic fibroblasts (MEFs), were neurally
induced by stromal cell-inducing activity. Before transplantation, the efficiency of neural induction and the
proportion of residual undifferentiated cells were evaluated using immunocytochemistry, and no significant
differences were observed in the ratios of colonies expressing βIII tubulin, nestin, or octamer (Oct)3/4. Four
weeks after transplantation into the cochleae of neonatal mice, the number of surviving transplants of TTF-
derived iPS cells generated by retroviral infection was significantly higher than those of MEF-derived iPS
cells generated by plasmid transfection. Teratoma formation was identified in one of five cochleae trans-
planted with TTF-derived iPS cells. However, no significant differences were found in the cell proliferation
activity or the extent of differentiation into mature neurons among the cell lines. These findings emphasize
the necessity of selecting appropriate iPS cell lines and developing methods to eliminate undifferentiated
cells after neural induction, in order to establish safe iPS cell-based therapy for the inner ear.
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INTRODUCTION (36,37,42), could be of great significance. Previous stud-
ies have investigated the potential of iPS cell-based ther-
apy for regenerative medicine in a variety of fields,Hearing loss affects millions of people worldwide
and is one of the most common disabilities. Hair cells including the nervous system (16,33,39,43), which
strongly suggests that they have an equivalent capacityand their associated auditory primary neurons, the spiral
ganglion neurons, are essential for hearing, and defects to ES cells.
We previously reported on the potential of ES cell-in these cells can result in profound hearing impairment
or deafness. Recent studies have indicated the potential derived neural progenitors, which had been neurally
induced by stromal cell-inducing activity (SDIA) (13),of stem cell-based approaches for the regeneration of
hair cells and spiral ganglion neurons, with embryonic as transplants for the replacement of spiral ganglion neu-
rons (17,18,24). We compared the capability of iPS cell-stem (ES) cells being identified as the most promising
stem cell candidate. Previously, ES cells have been used derived neural progenitors and ES cell-derived cells to
differentiate into spiral ganglion neurons (23), whichto generate glutamatergic neurons (30), neurons making
synaptic contacts with cochlear hair cells (17,18), and in suggested the possibility of substituting iPS cells for ES
cells in this instance. However, iPS cells have consider-vitro hair cell-like cells (15,27), as well as in the func-
tional recovery of transplanted cochleae in an animal able variation in their capacity for differentiation, and
there is a risk of tumorigenesis among their clonesmodel (24).
However, the use of ES cells introduces problems (19,41), which is a critical issue for clinical applications.
We previously used only one clone of iPS cells, andinvolving immune rejection and ethics. In this context,
the establishment of induced pluripotent stem (iPS) did not clarify the risk for tumorigenesis after cochlear
transplantation. Since then, numerous iPS clones havecells, which are generated from a patient’s own cells
Received November 25, 2010; final acceptance April 27, 2011. Online prepub date: February 2, 2012.
Address correspondence to Takayuki Nakagawa, M.D., Ph.D., Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medi-
cine, Kyoto University, Kawahara-cho 54, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel: +81-75-751-3346; Fax: +81-75-751-7225;
E-mail: tnakagawa@ent.kuhp.kyoto-u.ac.jp
763
764 NISHIMURA ET AL.
been generated using different transcription factor com- Antibodies
binations and sources (3,21,25,26). The current study The primary antibodies used were as follows: anti-
compared the survival and neural differentiation capabil- βIII tubulin mouse monoclonal antibody (1:500; Covance
ities, and the risk of tumorigenesis after cochlear trans- Research Products, Berkeley, CA); anti-nestin mouse
plantation, among mouse ES cells and three clones of monoclonal antibody (1:500; BD Pharmingen, Franklin
mouse iPS cells, which were generated using different Lakes, NJ); anti-octamer-binding transcription factor 3/4
sources and methods. (Oct3/4) mouse monoclonal antibody (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA); and anti-Ki67 rabbitMATERIALS AND METHODS
monoclonal antibody (1:500; Thermo Fisher Scientific
Animals Anatomical Pathology, Runcorn, UK). The secondary
Postnatal day 3 (P3) C57BL/6 mice (Japan SLC, antibodies used were Alexa-488-conjugated anti-mouse
Hamamatsu, Japan) were cared for in the Institute of or rabbit antibody (1:1000; Molecular Probes, Eugene,
Laboratory Animals at Kyoto University Graduate OR) and Alexa-568-conjugated anti-mouse or rabbit
School of Medicine in Japan. The Animal Research antibody (1:1000; Molecular Probes).
Committee of the Kyoto University Graduate School of
Neural InductionMedicine approved all of the experimental protocols,
SDIA was used for the neural induction of pluripo-which were performed in accordance with the National
tent stem cells (13), as reported previously (17,18,23,Institute of Health Guidelines for the Care and Use of
24). Undifferentiated iPS or ES cells were cultured toLaboratory Animals.
form differentiated colonies on a feeder layer of PA6
Cell Lines stromal cells (RCB1127; Riken Cell Bank, Kobe,
The cell lines used in this study are shown in Table Japan). Colonies that formed on the PA6 monolayer
1. These included three iPS cell lines, one of which was after 7 days of culture were isolated. Following fixation
generated by the retroviral transduction of adult mouse with 4% paraformaldehyde in 0.1 M phosphate buffer
tail-tip fibroblasts (TTFs) to produce 256H13 cells (21) for 15 min, immunostaining for βIII tubulin, nestin, and
carrying the Discosoma coral red fluorescent protein octamer (Oct)3/4 against undifferentiated and differenti-
(DsRed) gene driven by the cytomegalovirus early ated ES or iPS colonies was performed to test the effi-
enhancer/chicken β-actin (CAG) promoter. The other cacy of neural induction in each cell line. Specimens
two iPS cell lines were generated by the retroviral trans- were viewed with a BX50 microscope (Olympus,
duction of mouse embryonic fibroblasts (MEFs) to pro- Tokyo, Japan), and the number of βIII tubulin-, nestin-,
duce 20D17 cells (25), or by the plasmid transfection of or Oct3/4-positive colonies, as well as the total number
MEFs to produce 440A3 cells (26). We also used the of colonies, were counted. The ratio of βIII tubulin, nes-
mouse ES cell line G4-2 (generously donated by Dr. tin, or Oct3/4 expression was then calculated. Four inde-
Hitoshi Niwa, Riken CDB, Kobe, Japan), which was pendent cultures were performed.
derived from the E14tg2a ESC line (7) and carried the
Transplantation Procedureenhanced green fluorescent protein (EGFP) gene driven
by the CAG promoter (see Acknowledgments for source G4-2 ES cells and 256H13 iPS cells were genetically
labeled with GFP and DsRed, respectively. Colonies thatof cells).
Table 1. Summary of Cell Lines Used in This Study
Methods of
Gene Genes of
Cell Line Origin Transduction Transduction Cell Tracing Reference
Embryonic stem
G4-2 ICM — — CAG-EGFP 7
Induced pluripotent stem
20D17 MEF retrovirus Oct3/4, Klf4, Sox2, c-Myc DiI 25
440A3 MEF plasmid Oct3/4, Klf4, Sox2, c-Myc DiI 26
256H13 TTF retrovirus Oct3/4, Klf4, Sox2 CAG-DsRed 21
ICM, inner cell mass; MEF, mouse embryonic fibroblast; TTF, tail tip fibroblast; Oct3/4, octamer-binding transcription
factor 4; Klf4, Kru¨ppel-like factor 4; Sox2, (sex determining region Y)-box 2; c-Myc, myelocytomatosis; CAG-EGFP,
cytomegalovirus early enhancer/chicken β-actin promoter-enhanced green fluorescent protein; DiI, 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindocarbocyanine iodide.
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formed on the PA6 monolayer after 6 days of culture comparisons. Differences in the numbers of surviving
transplants in one midmodiolus section, and in the ratiowere isolated by incubation with collagenase B (Roche
Diagnostics, Tokyo, Japan) for 5 min at room tempera- of expression of βIII tubulin or Ki67 in surviving trans-
plants (G4-2, n = 2; 20D17, n = 5; 440A3, n = 4;ture. After dissociation of those isolated colonies into
single cells by treatment with 0.25% trypsin-ethylenedi- 256H13, n = 4) were statistically examined with one-
factor factorial ANOVA, followed by Tukey-Krameramine tetraacetic acid (EDTA) (Invitrogen) for 5 min at
37°C, 20D17 and 440A3 iPS cells were labeled with 5 test for multiple comparisons. Values of p < 0.05 were
considered to be statistically significant. All data areµg/ml 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbo-
cyanine perchlorate (DiI; Invitrogen) for 5 min at room presented as the mean ± SE.
temperature, and then for an additional 25 min at 4°C.
RESULTSAfter labeling, cells were washed with phosphate-
Efficacy of Neural Induction Before Transplantationbuffered saline (PBS) three times and resuspended at the
density of 1 × 104 cells/µl in fresh Dulbecco/Vogt modi- The expression of nestin or βIII tubulin was observed
fied Eagle’s minimal essential medium. SDIA-treated in colonies derived from each cell line following SDIA
cells were transplanted into C57BL/6 P3 mouse treatment (Fig. 1a–h), with typical filamentous struc-
cochleae (n = 20). Animals were anesthetized using a tures of the nestin at higher magnifications (Fig. 1a–d,
combination of general anesthesia with sevoflurane and insets). The expression of Oct3/4 was found in colonies
local anesthesia with 0.5% lidocaine. The left otic bulla derived from each cell line (Fig. 1i–l). The ratios of βIII
of each animal was opened to expose the round window, tubulin, nestin, or Oct3/4 expression before and after
and suspensions of each cell line (4 × 104 cells in 4 µl SDIA treatment are shown in Figure 2, with signifi-
Dulbecco/Vogt modified Eagle’s minimal essential cantly higher values of βIII tubulin and nestin expres-
medium) were injected into the scala tympani through sion after SDIA treatment, indicating efficient neural
the round window membrane, which was then covered induction. There were no significant differences in the
with fibrin glue. ratio of nestin or βIII tubulin expression among cell
lines. To identify undifferentiated cells in colonies after
Fates of Transplanted Cells neural induction by SDIA, Oct3/4 expression was exam-
SDIA-treated cells that had been transplanted into ined (Fig. 1i–l) and the ratios of expression were unex-
neonate mouse cochleae were examined 4 weeks after pectedly high (Fig. 2c) after SDIA treatment, implying
transplantation using immunohistochemistry. Under the presence of undifferentiated cells in colonies before
general anesthesia with sevoflurane, cochleae were dis- cell transplantation. No statistical differences in the ratio
sected out and fixed with 4% paraformaldehyde for 4 h. of Oct3/4 expression were found among cell lines. In
After decalcification with 10% EDTA for 5 days, 10- short, transplants derived from each cell line contained
µm-thick cryostat sections were made. Midmodiolus neural-induced and undifferentiated cells in approxi-
sections were provided for immunostaining for βIII mately similar ratios.
tubulin and Ki67. At the end of the staining procedures,
Fates of Transplantsnuclear staining was performed with 4′,6-diamino-2-
phenyl-indole (DAPI). Surviving transplants were Four weeks after transplantation, surviving trans-
plant-derived cells were found in two of the threedefined as labeled cells with normal nuclear morphol-
ogy, and the numbers of surviving transplants and βIII cochleae transplanted with ES cell-derived cells, five of
the six transplanted with 20D17 iPS cell-derived cells,tubulin- or Ki67-positive transplants were counted in
two midmodiolus sections of each cochlea. The average four of the six transplanted with 440A3 iPS cell-derived
cells, and four of the five transplanted with 256H13 iPSvalue for each animal was used in the analysis. The ratio
for the expression of βIII tubulin or Ki67 in surviving cell-derived cells (Fig. 3a–d). The high settlement rates
of transplant-derived cells in each cell line indicate thetransplants was calculated. In addition, hematoxylin and
eosin (H&E) staining was performed in four randomly stability of our transplantation procedure. No significant
differences in the presence of transplant-derived cellsselected sections to examine tumor generation in
the cochleae. were found among the cell lines, indicating no signifi-
cant difference in the capability for survival. Cochlear
Statistical Analysis specimens that showed the settlement of transplant-
derived cells were used for further histological analyses.Differences in the ratio of expression for βIII tubulin,
nestin, or Oct3/4 in the colonies before and after neural We observed the expression of βIII tubulin in trans-
plant-derived cells in each cell line (Fig. 3e–h), and theinduction (n = 4 for each group) were statistically exam-
ined with two-factor factorial analysis of variance ratios of expression are shown in Table 2. There were
no significant differences in these ratios among the cell(ANOVA), followed by Bonferroni test for multiple
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Figure 1. In vitro neural differentiation of embryonic stem (ES) cells (ES) and induced pluripotent stem (iPS) cells by stromal
cell-derived inducing activity (SDIA). Immunocytochemical analysis of colonies following SDIA treatment for nestin (a–d), for
βIII tubulin (e–h), and for octamer-binding transcription factor 3/4 (Oct3/4) with 4′,6-diamino-2-phenyl-indole (DAPI) counterstain-
ing of nuclei (i–l). Insets (a–d) demonstrate the filamentous staining pattern of the nestin antibody. Scale bar: 100 µm. Inset scale
bar: 20 µm. See text and tables for definition of cell types.
lines, suggesting that they all have a similar ability to line-derived cells (Fig. 4). This tumor contained both
undifferentiated cells and differentiated cells such asreplace neurons in the cochlea. Ki67 expression, which
is a marker of proliferating cells, was also observed in duct-forming epithelial cells, cartilage, neural cells, and
mesenchymal cells (Fig. 4). The remaining fourtransplant-derived cells of each cell line (Fig. 3i–l), indi-
cating that the proliferative capacity of SDIA-treated cochleae transplanted with 256H13 iPS cell line-derived
cells exhibited no tumor formation, similar to thecells was maintained 4 weeks after transplantation. The
ratios of Ki67 expression are shown in Table 2, and did cochleae transplanted with other cell line-derived cells.
not differ significantly between the cell lines, suggesting
DISCUSSIONno significant difference in proliferative activity. How-
ever, there was a significant difference among the cell Here we compared the neural differentiation capabil-
ity and the risk of tumorigenesis after cochlear trans-lines in the numbers of transplant-derived cells in the
cochleae: the number of transplant-derived 256H13 iPS plantation among three clones of iPS cells and ES cells.
Before transplantation, the efficacy of neural inductioncells was significantly higher than that of 440A3 iPS cells.
Teratoma formation was identified only in one and the proportion of residual undifferentiated cells after
SDIA treatment were evaluated using marker proteinscochlea that had been transplanted with 256H13 iPS cell
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such as nestin, βIII tubulin, and Oct3/4. SDIA was
shown to induce the neural differentiation of MEF- and
TTF-derived iPS cells, as well as ES cells. Unexpect-
edly, colonies derived from each cell line contained
residual undifferentiated cells even after neural induc-
tion, indicating that transplants derived from such cell
lines also contained undifferentiated cells. Presumably,
some of the SDIA-treated cells may express both pluri-
potent and neuronal markers, in accordance with a
recent study that neural precursor cells derived from
human embryonic and fetal central nervous system
expressed mRNA for pluripotent markers (35). No sig-
nificant differences in the ratios of marker protein
expression were identified among the cell types, sug-
gesting no apparent difference in the quality of trans-
plants before cochlear transplantation.
Four weeks after transplantation, the majority of
cochleae that had been transplanted exhibited the settle-
ment of iPS or ES cell-derived neurons, similar to previ-
ous studies (23,24). The ratio of βIII tubulin expression
in transplant-derived cells did not differ among cell
lines, suggesting that all three of the iPS cell lines stud-
ied had a similar capability to ES cells for the settlement
of stem cell-derived neurons in cochleae, as we observed
in a previous study (23).
We investigated the proliferative activity after
cochlear transplantation by immunostaining for Ki67.
Interestingly, 4 weeks after transplantation, transplant-
derived cells with proliferation activity were present in
cochleae that had undergone transplantation with all cell
types, including ES cells. Moreover, no difference in the
ratio of Ki67-positive cells in the transplant-derived
cells was identified among the cell lines. Previous
reports describing the transplantation of ES cell-derived
cells into cochleae found no tumor formation (1,2,4–
6,8,9,14,24,28–30,32), suggesting that the observed pro-
liferative activity of transplant-derived cells might not
be directly associated with the risk of tumorigenesis.
By contrast, the number of transplant-derived cells in
the cochleae differed among the cell lines. Although
there was no significant difference between the two
MEF-derived clones of iPS cells, iPS cells derived from
TTFs using retrovirus gave rise to significantly higher
cell numbers in transplants than iPS cells derived from
Figure 2. Efficacy of neural induction by SDIA. Percentages MEFs using plasmids. However, there is a possibility
of βIII tubulin-positive (a), nestin-positive (b), or Oct3/4-posi-
that the difference in cell tracing methods (TTFs withtive (c) ES and iPS cell colonies before and after SDIA treat-
CAG-DsRed expression vs. MEFs with DiI tracing)ment. Significantly higher values of βIII tubulin (a) and nestin
(b) expression were observed after SDIA treatment, with no affected the number of transplants after transplantation.
significant differences among cell lines. Percentages of Oct3/ In addition, in 1 out of 20 transplantation experiments,
4-positive colonies decreased significantly after SDIA treat- teratoma formation was observed only in one cochlea
ment, with no significant differences among cell lines (c).
that had been transplanted with retrovirally induced
*p < 0.05, **p < 0.01, ***p < 0.001.
TTF-derived iPS cells. Retroviral integration of the
exogenous transcription factors may activate or inacti-
vate host genes, resulting in tumorigenicity in the
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Figure 3. In vivo neural differentiation and proliferation of ES and iPS cell-derived neural progenitors. Enhanced green fluorescence
protein (EGFP) expressing ES cell-derived transplants were found in the scala tympani (arrows in a). DiI-positive iPSC-derived
cells were found in the scala tympani (arrows in b, c). Discosoma red fluorescent protein (DsRed)-expressing iPSC-derived trans-
plants were found in the scala tympani (arrow in d), in the scala media (arrowheads in d), and in the scala vestibuli (winding
arrows in d). Blue fluorescence shows nuclear labeling with 4′,6-diamino-2-phenyl-indole (DAPI). Immunohistochemical analysis
of markers for neurons (βIII tubulin) (e–h) and a marker for cell proliferation (Ki67) (i–l) in the C57BL/6 mouse cochlea 4 weeks
after transplantation. Arrows (e–h) and arrowheads (i–l) indicate βIII tubulin- or Ki67-positive transplants, respectively. Scale bars:
500 µm (a–d) , 10 µm (e–l). st, scala tympani; sm, scala media; sv, scala vestibuli; mo, modiolus.
cochlea, as was the case in some patients who under- cells (6,28,32) and fetal or adult neural stem cells (10–
12,38,40) into cochleae was not found to result in tumorwent gene therapy (22). Another possibility is that TTF-
derived iPS cells have a higher risk for tumorigenesis formation. The number of cells that can be transplanted
into cochleae is limited because of their tiny size, andthan MEF-derived iPS cells, which is consistent with
previous observations of transplantation into nonobese the numbers of settled transplant-derived cells in
cochleae are reportedly low (4,20,34). Therefore, thediabetic/severe combined immune deficiency (NOD/
SCID) mouse brains (19). risk for settlement of undifferentiated cells after trans-
plantation appears to be small. Notably, teratoma forma-To our knowledge, this is the first documentation of
teratoma formation in cochleae after cell transplantation. tion in the cochlea was identified after transplantation of
TTF-derived iPS cells, suggesting that their use involvesPreviously, the transplantation of undifferentiated ES
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Table 2. Characterization of Transplants After Transplantation
βIII Tubulin (%) Ki67 (%) Cell Number
Embryonic stem cells
G4-2 (n = 2) 27.5 ± 5.0 8.0 ± 5.0 985.5 ± 436.5
Induced pluripotent stem cells
20D17 (n = 5) 18.8 ± 4.2 10.5 ± 1.8 638.4 ± 103.3
440A3 (n = 4) 15.3 ± 2.2 8.1 ± 2.7 432.5 ± 289.3
256H13 (n = 4) 20.1 ± 1.2 7.2 ± 2.1 1537.0 ± 258.0
Data were compared with one-factor factorial analysis of variance (ANOVA), followed by
Tukey-Kramer test for multiple comparisons. The number of transplant-derived 256H13 iPS
cells was significantly higher than that of 440A3 iPS cells.
*p < 0.05.
a relatively high risk of tumorigenesis. Miura et al. vali- of iPS cell-based therapy, although further systematic
investigation is necessary to determine the risk fordated the risk for tumorigenesis of iPS cell lines follow-
ing neural induction, and indicated that their origin is a tumorigenesis in the cochlea. The elimination of undif-
ferentiated cells from transplants and/or the selection ofkey element for tumorigenesis, in association with the
persistence of undifferentiated cells (19,41). The present pure progenitors must also be considered. This could be
achieved by combining fluorescence-activated cell sort-finding supports this hypothesis.
Recent studies have demonstrated that iPS cells have ing with a recently reported novel method to track dif-
ferentiating neural progenitors in pluripotent culturesa similar capability to ES cells for the generation of
inner ear cells (23,27). These previous findings support using microRNA-regulated lentiviral vectors (31).
the development of iPS cell-based therapy for inner ears,
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